Liver transplantation recipients (LTRs) who are seropositive for cytomegalovirus (CMV) (recipient seropositive [R1]) are at intermediate risk for CMV disease. A preventative strategy following transplant is considered standard of care. Current guidelines recommend high-dose valganciclovir (VGCV; 900 mg/day adjusted for renal function) for prophylaxis given limited data on the efficacy and safety of low-dose VGCV (450 mg/day adjusted for renal function). We describe our experience using low-dose VGCV prophylaxis for R1 LTRs at our institution. A single-center, retrospective study was conducted using a database of 364 LTRs over a 4-year period (2011)(2012)(2013)(2014). Adult first-time R1 LTRs receiving low-dose VGCV prophylaxis were included. The primary endpoint was CMV disease at 1 year after transplant. Patients were compared with historical controls receiving high-dose VGCV prophylaxis. Secondary endpoints were biopsy-proven rejection and leukopenia on VGCV. With respect to leukopenia, patients receiving low-dose VGCV were compared with a group of D1R-patients from the database receiving high-dose VGCV. Univariate analyses were performed using chi-squared, Fisher's exact, and Wilcoxon rank sum tests. A total of 200 R1 LTRs met inclusion criteria. Median age was 60 years (interquartile range [IQR], 54-66 years), and 129 (65%) LTRs were male. Median Model for End-Stage Liver Disease score was 22 (IQR, 14-31), and 178 (89%) patients received deceased donor transplants. CMV disease occurred in only 9 (5%) patients, similar to rates in previous studies of LTRs receiving high-dose VGCV. Biopsy-proven rejection occurred in 18 (9%) patients. Patients received VGCV prophylaxis for a median of 3.4 (IQR, 3.1-4.3) months; 151 (76%) R1 LTRs receiving low-dose VGCV developed leukopenia. Premature VGCV discontinuation and granulocyte-colony stimulating factor use were infrequent and not significantly different between the 2 groups. In conclusion, low-dose VGCV was safe and effective for prevention of CMV disease in our cohort of 200 R1 LTR and should be considered as an option in future guidelines.
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Received September 17, 2017 ; accepted February 25, 2018. Cytomegalovirus (CMV) can cause direct and indirect adverse effects in liver transplantation recipients (LTRs).
(1) Direct effects range from a viral syndrome to end-organ disease; indirect (immunomodulatory) effects include graft dysfunction and increased risk for opportunistic infections. (2) LTRs who are seropositive for CMV (recipient seropositive [R1]) are considered to be at intermediate risk for CMV disease. (3) The risk is highest 1-6 months after transplant, with 8%-18% of R1 LTRs developing CMV disease without prophylaxis. (4) A preventative strategy following transplant is considered standard of care; approaches include preemptive therapy and universal prophylaxis. (5) Valganciclovir (VGCV), the oral prodrug of ganciclovir (GCV), is the most frequently used agent for prophylaxis. (6) The major adverse effect of VGCV is bone marrow suppression leading to severe leukopenia. Current guidelines (8) recommend using high-dose VGCV (900 mg/day adjusted for renal function) for prophylaxis given limited data on the efficacy and Abbreviations: AIH, autoimmune hepatitis; CMV, cytomegalovirus; CrCl, creatinine clearance; D-, donor seronegative; D1, donor seropositive; DDLT, deceased donor liver transplantation; FHF, fulminant hepatic failure; G-CSF, granulocyte-colony stimulating factor; GCV, ganciclovir; GI, gastrointestinal; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; LDLT, living donor liver transplantation; LT, liver transplantation; LTR, liver transplantation recipient; MELD, Model for End-Stage Liver Disease; MMF, mycophenolate mofetil; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; R-, recipient seronegative; R1, recipient seropositive; safety of low-dose VGCV (450 mg/day adjusted for renal function). However, in a survey of CMV management in organ transplantation, (6) over one-third of respondents reported using low-dose VGCV prophylaxis in CMV donor seropositive (D1) R1 organ transplant recipients.
A meta-analysis (9) of organ transplant recipients receiving low-versus high-dose VGCV prophylaxis found no difference in efficacy and lower rates of rejection and leukopenia in the low-dose group; however, only 239 LTRs were included in 3 of 20 studies. Recent studies comparing low-versus high-dose VGCV prophylaxis in R1 renal transplant recipients (RTR) found no significant differences in CMV disease, rejection, or graft loss between the 2 groups (10) and fewer episodes of leukopenia in the low-dose group. (11) There is a paucity of data on the use of low-dose VGCV in R1 LTRs. Park et al. (12) retrospectively reviewed 45 R1 LTRs receiving low-dose VGCV prophylaxis; only 1 patient developed CMV disease up to 1 year after transplant. Dupuis et al. (13) reviewed 71 R1 LTRs receiving low-dose VGCV prophylaxis; 7 (10%) patients developed CMV infection, 4 (6%) of whom had CMV disease.
We have used low-dose VGCV prophylaxis for CMV in R1 LTRs at our institution and herein describe our experience. We hypothesized that low-dose VGCV would be effective at preventing CMV disease and would be potentially safer with respect to leukopenia.
Patients and Methods

STUDY DESIGN
A single-center, retrospective study was conducted at The Mount Sinai Hospital, a large tertiary academic medical center in New York City. A database of 364 LTRs from 2011 to 2014 was accessed and reviewed via electronic medical records (Epic Systems, Verona, WI). CMV recipient seronegative (R-) LTRs and patients with retransplants, liver-kidney transplants, human immunodeficiency virus (HIV), or those in whom CMV serostatus or duration of VGCV exposure could not be confirmed were excluded. CMV R1 adult patients (age 18 years) with a first-time liver transplantation (LT) were included. All R1 LTRs received universal prophylaxis with low-dose VGCV and baseline maintenance immunosuppression with tacrolimus, mycophenolate mofetil (MMF), and prednisone as per institutional protocol. Historical controls of R1 LTRs receiving high-dose VGCV at our institution were not available because we have always used low-dose VGCV prophylaxis in this group. Therefore, a literature search was conducted on PubMed using the keywords valganciclovir, prophylaxis, liver, and transplant to identify studies of historical controls of R1 LTRs who received high-dose VGCV (or the equivalent dose of GCV) prophylaxis. This study was approved by the Mount Sinai Medical Center institutional review board.
Low-dose VGCV prophylaxis was defined based on institutional protocol as 450 mg/day adjusted for renal function (450 mg/day for creatinine clearance [CrCl] 40; 450 mg every other day for CrCl 25-39 mL/min; and 450 mg twice per week for CrCl 24 mL/min). The recommended duration of prophylaxis was 3 months. Patients treated for rejection had the option to extend their prophylaxis by an additional 3 months. Adjustments in VGCV dose or duration were made at the discretion of individual providers.
Updated consensus definitions (14) were used for CMV disease, which required the presence of clinical signs or symptoms as well as detection of virus in any body fluid or tissue. CMV gastrointestinal (GI) disease was further divided into 3 categories:
1. Proven (symptoms along with macroscopic mucosal lesions and CMV isolated or detected via tissue culture, histopathology, immunohistochemical stains, or DNA hybridization). 2. Probable (symptoms and CMV isolated or detected via tissue culture, histopathology, immunohistochemical stains, or DNA hybridization, minus macroscopic mucosal lesions). 3. Possible (symptoms and CMV DNAemia).
CMV syndrome was defined as DNAemia plus at least 2 of the following: fever of >388C for 2 days, new malaise or fatigue, leukopenia or neutropenia on 2 separate measurements, 5% atypical lymphocytes on differential, or thrombocytopenia.
STUDY ENDPOINTS
The primary endpoint was CMV disease occurring up to 1 year after transplant. Our rates in patients receiving low-dose VGCV prophylaxis were compared with rates in historical controls who received high-dose VGCV (or the equivalent dose of GCV) prophylaxis. Breakthrough CMV disease was defined as disease occurring during VGCV prophylaxis. Postprophylaxis CMV disease was defined as disease occurring within 6 months after completion of prophylaxis. Secondary endpoints were biopsy-proven rejection and leukopenia (defined as <4000 white blood cell [WBC]/mL) while on VGCV. With respect to leukopenia, patients receiving low-dose VGCV were compared with patients receiving high-dose VGCV (900 mg/day adjusted for renal function). Premature discontinuation of VGCV, use of granulocyte-colony stimulating factor (G-CSF) due to leukopenia, and WBC nadir while on VGCV were also analyzed.
STATISTICAL ANALYSIS
Categorical variables were described using frequencies and proportions. Continuous variables were described with median and interquartile range (IQR). Univariate analyses were performed with Pearson's chi-squared, Fisher's exact, or Wilcoxon rank sum test, as applicable. Analyses were performed in Stata MP, version 14.1 (StataCorp, College Station, TX). All tests were 2-sided, and P < 0.05 was considered statistically significant.
Results
Of 364 LTRs from 2011 to 2014, a total of 164 were excluded: 65 were CMV R-, 15 were retransplants, 14 were combined liver-kidney transplants, 9 had HIV, 24 had unknown CMV serostatus, 16 had unknown duration of VGCV exposure, 16 were lost to followup, 3 received pre-emptive therapy, 1 was a pediatric patient, and 1 was R1 but did not receive VGCV.
A total of 200 R1 LTRs met inclusion criteria. Table 1 .
CMV DNAemia occurred in 15 (8%) patients; 6 (3%) of these patients were asymptomatic; none of the 6 patients developed CMV disease up to 1 year after transplant. One patient had breakthrough DNAemia in the setting of rejection and was switched to treatment-dose antiviral therapy. The other 5 patients occurred after prophylaxis.
CMV disease occurred in 9 (5%) patients; 7 (6%) were D1R1; and 2 (3%) were donor seronegative (D-) R1. Two (1%) patients had CMV syndrome; 1 (1%) patient had proven CMV GI disease; and 6 (3%) patients had possible CMV GI disease. Only 2 patients had breakthrough CMV disease, and both were cases of possible CMV GI disease: 1 in a D1R1 patient and 1 in a D-R1 patient. CMV resistance testing was not performed because both patients responded to treatment doses of VGCV. There were 6 patients with postprophylaxis CMV disease, occurring a median of 77 days (IQR, 38-94 days) following completion of prophylaxis. A study endpoint of CMV disease at 1 year after transplant was used. NOTE: Data are given as n (%) or median (IQR). *Other includes cryptogenic cirrhosis, 9 (4.5%); PBC, 9 (4.5%); FHF, 8 (4%); AIH, 4 (2%); and PSC, 2 (1%).
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A literature search identified 4 studies (15) (16) (17) (18) of historical controls of R1 LTRs receiving high-dose VGCV (or the equivalent dose of GCV) prophylaxis. Immunosuppressive regimens were similar to our cohort. Prophylactic regimens varied between the studies and included VGCV 900 mg/day for 90-100 days or oral GCV 1g 3 times per day (tid). Three of the studies (15) (16) (17) had similar CMV disease rates compared with our cohort (5%); 1 study (18) had a significantly higher CMV disease rate compared with our cohort (13% versus 5%, P 5 0.005). Findings are summarized in Table 2 .
A total of 18 (9%) R1 LTRs developed biopsyproven rejection within 1 year of transplant: 12 (10%) D1R1 patients and 6 (8%) D-R1 patients. Two (11%) patients with rejection also had CMV disease: 1 D1R1 patient with breakthrough possible GI CMV disease occurring 24 days prior to rejection diagnosis and 1 D1R1 patient with CMV syndrome occurring 9 days before rejection was diagnosed.
A total of 151 (76%) R1 LTRs developed leukopenia during VGCV prophylaxis. VGCV was prematurely discontinued in 12 (6%) patients, and 12 (6%) patients received G-CSF while on VGCV. With respect to leukopenia, the group of 200 R1 patients receiving low-dose VGCV was compared with a group of 25 patients receiving high-dose VGCV (24 D1R-and 1 D1R1). There were no differences in leukopenia on VGCV (76% versus 80%; P 5 0.66), premature discontinuation of VGCV (6% versus 0%; P 5 0.37), G-CSF use (6% versus 8%; P 5 0.65), or WBC nadir (2.5 versus 2.3; P 5 0.35) between the low-dose and high-dose groups, respectively (Table 3) . On univariate analysis, VGCV dose (450 versus 900 mg; P 5 0.81), recipient serostatus (R1 or R-; P 5 0.82), and presence or absence of CMV disease (P 5 0.58) were not associated with leukopenia.
Discussion
Our study demonstrates that low-dose VGCV is effective at preventing CMV disease in intermediate-risk LTRs with very low rates of CMV disease (5%) up to 1 year after transplant in our cohort. This is similar to rates that have been reported in previous smaller studies of R1 LTRs receiving low-dose VGCV prophylaxis (12, 13) and in historical controls of R1 LTRs receiving high-dose VGCV prophylaxis, (15) (16) (17) (18) and it is substantially lower than rates without prophylaxis. (4) A meta-analysis of high-risk (D1R-) LTRs (19) found a Not specified which patients received VGCV versus GCV; no significant difference in CMV disease incidence between VGCV and GCV groups.
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2-fold lower risk of CMV disease in patients receiving low-dose VGCV prophylaxis compared with highdose prophylaxis; they speculate this may be due to low-level exposure to CMV antigen and development of cellular immunity in the low-dose group. In a separate meta-analysis of organ transplant recipients, (9) the authors found lower rates of biopsy-proven rejection with low-dose VGCV prophylaxis, which they interpreted as mitigated indirect effects of CMV.
In addition to the 9 patients with CMV disease, 6 patients developed asymptomatic CMV DNAemia. A recent review and meta-analysis (20) found that DNAemia is predictive of CMV disease-the authors note that the incidence of DNAemia and disease is significantly lower during prophylaxis and treatment of (asymptomatic) CMV DNAemia prevents disease. None of the patients with asymptomatic DNAemia in our cohort developed CMV disease up to 1 year after transplant. One patient had breakthrough DNAemia in the setting of rejection, received antiviral therapy, and did not develop CMV disease during the follow-up period.
There were only 2 patients with breakthrough CMV disease in our study, and both were cases of possible GI CMV disease that resolved with initiation of treatment-dose VGCV; resistance testing was neither indicated nor performed. Although higher rates of breakthrough CMV disease have been reported in high-risk RTR when switching from high-dose to low-dose VGCV prophylaxis, (21) this has not been reported in intermediate-risk patients or in LTRs. The association of low-dose VGCV with increased breakthrough or resistant CMV remains a gap in knowledge and warrants further investigation.
In addition to dosage, prophylaxis duration has been shown to be a significant factor in prevention of CMV disease in RTRs. The IMPACT study (22) demonstrated that extending prophylaxis from 100 to 200 days after transplantation in D1R-RTR significantly decreased the 2-year incidence of CMV disease (21% versus 39%; P < 0.001). Fayek et al. (23) showed that low-dose VGCV prophylaxis extended for a duration of at least 12 months was effective at preventing CMV disease in the same population with no cases of lateonset CMV disease or increased antiviral resistance. Whether there is a role for extended-duration prophylaxis in LTR remains to be investigated. Most patients received VGCV prophylaxis for 3 months in our study. There were 6 patients with postprophylaxis CMV disease; patients were only followed 1 year after transplant, so the true incidence of late-onset disease is unknown. Prevention of late-onset CMV disease in LTR remains an area of uncertainty.
Over three-quarters of patients in our cohort developed leukopenia while receiving low-dose VGCV. This is comparable to rates in a study of LTRs (over twothirds of whom were R1) receiving high-dose VGCV prophylaxis, where 69% of patients developed leukopenia (24) ; the authors used a cutoff of <3000 WBC/mL to define leukopenia, so arguably, their rates would be even higher if using our cutoff of 4000 WBC/mL. Although leukopenia was common with both low-dose and highdose VGCV in our cohort, it was rarely clinically significant as demonstrated by low rates of premature VGCV discontinuation and G-CSF use in leukopenic patients. There are multiple etiologies of leukopenia both before and after transplant in the LTR population, including host factors (age, cirrhosis), medication-induced myelosuppression (MMF, trimethoprim-sulfamethoxazole, VGCV) as well as CMV itself. (25) In univariate analyses, leukopenia was not associated with VGCV dose, recipient serostatus, or CMV disease, in contrast to other studies in organ transplant recipients (9, 11) that found VGCV dose to be inversely proportional to WBC count.
There were 7841 liver transplants performed in the United States in 2016, and the number is growing. Although we did not perform a formal cost-avoidance calculation in our study, given an estimated CMV seroprevalence of over 50% in the United States (27) and an average retail price of $3061 for a 30-day supply of high-dose VGCV prophylaxis, (28) the expected cost avoidance with using low-dose VGCV prophylaxis in R1 LTRs is likely to be significant.
Our study has several limitations. Our single-center experience may not be applicable to other institutions. Our study was conducted retrospectively and did not a have a comparison group of R1 LTRs receiving highdose VGCV; historical controls were used instead. Direct comparison to these studies has significant limitations given heterogeneity in the prophylactic regimens and baseline patient characteristics; 1 of the studies (16) did not specify if any D-R-patients were included so comparison to this study is limited even further. Renal dose adjustments were at the discretion of individual providers and not controlled for in this retrospective study. The sample size of patients receiving high-dose VGCV in our study was small and most of these patients were D1R-; therefore, conclusions about VGCV dose and leukopenia are limited. We excluded patients with retransplants, liver-kidney transplants, and HIV, and thus, we cannot extrapolate our findings to these groups. Finally, patients were only followed 1 year after transplant, so the incidence of late-onset CMV disease in our cohort is unknown. Prevention of CMV disease in LTRs is a rapidly evolving field. A multicenter trial of pre-emptive therapy versus universal prophylaxis in LTR is ongoing, (29) as are endeavors to develop a CMV vaccine (30) and CMV-specific T cell response assays to tailor prophylactic strategies to individual patients. (31) Pending the impact of these studies on our approach to CMV prevention, we conclude that low-dose VGCV is safe and effective for universal prophylaxis in intermediate-risk LTRs and should be considered a recommended option in future guidelines.
